Biotech Focus Target venture opportunities with SR One Capital Management, a transatlantic biotech VC/PE firm that partners with top entrepreneurs and scientists to translate innovative technologies into next-generation medicines, signaling interest in late-stage or breakthrough biotech startups with clear clinical unmet needs.

Active Portfolio Expansion Leverage SR One’s recent and ongoing investments in Antag Therapeutics, Windward Bio, Charm Therapeutics, Zenas BioPharma, Nimbus Therapeutics, Fore Biotherapeutics, and Rezo Therapeutics to identify co-investment, commercialization, or strategic collaboration opportunities with portfolio companies seeking capital, partnerships, or acquisition strategies.

Strategic Geography Engage SR One’s transatlantic footprint with San Francisco and London offices to pursue cross-border deals, licensing, or joint ventures that leverage UK and US biopharma ecosystems, talent pools, and regulatory pathways.

Funding Scale Position opportunities around stages and financing needs aligned with SR One’s demonstrated investment activity, from Series A to Series B/C, and potential follow-ons, given their participation as lead or co-lead investor in multi-million dollar rounds.

Tech and Data Enablement Highlight potential value from SR One’s tech-enabled operations and portfolio company tech approaches by offering digital health, computational drug discovery, or data science partnerships that can accelerate research or optimize portfolio diagnostics and biomarker strategies.